Home > Diseases and Conditions > Lambert-Eaton syndrome
Bookmark and Share

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

A.D.A.M. Medical Encyclopedia. Atlanta (GA): A.D.A.M.; 2011.

A.D.A.M. Medical Encyclopedia.

Lambert-Eaton syndrome

Myasthenic syndrome; Eaton-Lambert syndrome; Lambert-Eaton myasthenic syndrome; LEMS

Last reviewed: August 27, 2010.

Lambert-Eaton syndrome is a disorder in which faulty communication between nerves and muscles leads to muscle weakness.

Causes, incidence, and risk factors

Lambert-Eaton syndrome occurs when nerves cells do not release enough of a chemical called acetylcholine. This chemical transmits impulses between nerves and muscles.

The result is muscle weakness and other symptoms similar to myasthenia gravis. However, unlike myasthenia gravis, as the muscles continue to contract, acetylcholine can build up in large enough amounts for strength to improve slightly. Instead of the muscle getting quickly weaker as it contracts repeatedly, it gets stronger for a short period of time.

Lambert-Eaton syndrome may occur with cancers such as small cell lung cancer or autoimmune disorders such as vitiligo, which leads to a loss of skin pigment.

Symptoms

Symptoms may include:

  • Weakness or loss of movement that can be more or less severe, including:

    • Difficulty chewing

    • Difficulty climbing stairs

    • Difficulty lifting objects

    • Difficulty talking

    • Drooping head

    • Need to use hands to get up from sitting or lying positions

  • Swallowing difficulty, gagging, or choking

  • Vision changes such as:

    • Blurry vision

    • Double vision

    • Problems keeping a steady gaze

Symptoms related to the autonomic nervous system usually occur, and include:

  • Blood pressure changes

  • Dizziness upon standing

  • Dry mouth

Signs and tests

A detailed medical history will be taken to determine risk factors, such as a history of certain cancers.

A physical examination shows:

  • Decreased reflexes

  • Possible loss of muscle tissue

  • Weakness or paralysis that gets slightly better with activity

Tests to help diagnose and confirm the condition may include:

Treatment

The main goals of treatment are to:

  • Identify and treat any underlying disorders, such as lung cancer

  • Give treatment to help with the weakness

A treatment called plasma exchange usually improves symptoms. Plasma exchange involves removing blood plasma from the body and replacing it with donated plasma. This helps to make sure that any harmful proteins (antibodies) that are interfering with nerve function are removed from the body.

Plasmapheresis may also be effective. During this treatment, the blood is removed from the body. The plasma is separated, the antibodies are removed, and the plasma is returned to the body.

Medications that suppress the immune response, such as prednisone, may improve symptoms in some cases. Medications may also include:

  • Anticholinesterase medications such as neostigmine or pyridostigmine (although these are not very effective when given alone)

  • 3, 4-diaminopyridine, which increases the release of acetylcholine from nerve cells

Expectations (prognosis)

The symptoms of Lambert-Eaton syndrome may improve by treating the underlying disease, suppressing the immune system, or removing the antibodies. However, not everyone responds well to treatment.

Complications

  • Difficulty breathing, including respiratory failure

  • Difficulty swallowing

  • Infections, such as pneumonia

  • Injuries from falls and problems with coordination

Calling your health care provider

Call your health care provider if symptoms of this condition develop.

References

  1. Vincent A, Newsom-Davis J. Disorders of neuromuscular transmission. In: Goldman L, Ausiello D, eds. Cecil Medicine. 23rd ed. Philadelphia, Pa: Saunders Elsevier; 2007:chap 448.

Review Date: 8/27/2010.

Reviewed by: David C. Dugdale, III, MD, Professor of Medicine, Division of General Medicine, Department of Medicine, University of Washington School of Medicine; and Daniel B. Hoch, PhD, MD, Assistant Professor of Neurology, Harvard Medical School, Department of Neurology, Massachusetts General Hospital. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.

A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only — they do not constitute endorsementscof those other sites. © 1997–2011 A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.

Copyright © 2012, A.D.A.M., Inc.

What works?

  • Treatment for Lambert‐Eaton myasthenic syndrome Treatment for Lambert‐Eaton myasthenic syndrome
    Lambert‐Eaton myasthenic syndrome (LEMS) is a rare disorder of the neuromuscular junction that causes muscle weakness (most commonly in the upper arms and legs). It is an autoimmune disease in which the body's own antibodies prevent the release of the chemical acetylcholine. This interferes with transmission of nerve impulses to the muscles. One of the main treatments is 3,4‐diaminopyridine which increases the release of acetylcholine. Four small randomised controlled trials involving 54 participants in total showed that 3,4‐diaminopyridine improves muscle strength. This was determined by measuring the compound muscle action potential (CMAP) which is a test that records the amount of electrical activity generated in a muscle when it is stimulated by its nerve. Although the number of trials is relatively small, the quality of evidence from these trials is moderate to high, which supports the findings of this review. The changes are measured over days only. A single trial involving nine participants showed that intravenous immunoglobulin also improved muscle strength up to 8 weeks from treatment. Other possible treatments such as plasma exchange, steroids and immunosuppressive agents have not been tested in randomised controlled trials. Further trials of these treatments are needed.
See all (1)...

Figures

  • Superficial anterior muscles.

In the news

  • Image for UK NHS headline Clot risk of contraceptive patch examined
    11 May 2012
    “Women using a vaginal ring or skin patch for contraception are at around double the risk of a blood clot compared to those taking the Pill,” says the Daily Mail. The news is based on a large Danish ...
more...

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...